Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on August 2, 2012. The report serves to announce the Company's financial results for the second quarter of 2012. The filing references a press release (Exhibit 99.1) containing the detailed results.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of Q2 2012 results.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific Q2 2012 financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release).
- Confirm the Company's current cash runway and burn rate, as these are critical for a biopharmaceutical entity but are not detailed in this summary text.
- Review the full press release for any updates on clinical trial progress or regulatory milestones that may impact future valuation.
- Note the legal disclaimer that the financial data in this 8-K is "furnished" rather than "filed," which may affect liability standards.